摘要
酒精中毒尤其是对于青少年来说是一个日益严重的问题。目前,虽然已有多种药物治疗方法治疗酒精中毒,但只有少数方法表现出显着的疗效。纳美芬,一个结合阿片μ受体的拮抗作用和κ受体部分激动剂的新化合物,最近被欧洲药品管理局批准用于治疗酒精中毒。这种药物可以减少酒精的摄入量,因此,它可以被认为是戒酒的第一步和基本步骤之一。本综述的目的是对有关纳美芬的文献和对这治疗酒瘾(及其他上瘾)的治疗方法进行归纳总结。更多内容请访问:
关键词: 酒精中毒,药物治疗,纳美芬,阿片类药物,奖赏系统。
Current Medicinal Chemistry
Title:Nalmefene: A Novel Drug for an Old Disorder
Volume: 22 Issue: 27
Author(s): Donatella Marazziti, Silvio Presta, Stefano Baroni, Francesco Mungai, Armando Piccinni, Federico Mucci and Liliana Dell’Osso
Affiliation:
关键词: 酒精中毒,药物治疗,纳美芬,阿片类药物,奖赏系统。
摘要: Alcoholism is an increasing problem all over the world, and nowadays especially amongst teenagers. Although several drug treatments have been proposed for this condition, only a few have demonstrated a significant efficacy. Nalmefene, a novel compound that combines opioids mu-receptors antagonism and kappa-receptors partial agonism, was recently approved by the European Medicine Agency for the treatment of alcoholism. This drug can be very helpful in reducing the alcohol intake, and, as such, it can be considered one of the first and fundamental steps towards alcohol abstinence. The aim of this review is to discuss and comment on the available literature on nalmefene, as well as on novel treatment strategies of this condition (and perhaps of other addictions) opened by this latest pharmacological approach.
Export Options
About this article
Cite this article as:
Donatella Marazziti, Silvio Presta, Stefano Baroni, Francesco Mungai, Armando Piccinni, Federico Mucci and Liliana Dell’Osso , Nalmefene: A Novel Drug for an Old Disorder, Current Medicinal Chemistry 2015; 22 (27) . https://dx.doi.org/10.2174/0929867322666150821100538
DOI https://dx.doi.org/10.2174/0929867322666150821100538 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modulating Agents in Resistant Malaria
Drug Design Reviews - Online (Discontinued) Five Markers Capable to Identify Passive Smoking Exposure Associated with Endothelial Dysfunction in Healthy Individuals
Current Hypertension Reviews The Negative Influence of Socio-Technical Developments on Eating Habits and Health
Current Nutrition & Food Science Editorial - Coping with Neuropathic Pain: Do We Need More Selective Analgesic Drugs?
Current Pharmaceutical Design Serum Interleukin-33 is a Predictor of Depression in Patients with Acute Ischemic Stroke
Current Neurovascular Research Recent Advances in Protein and Peptide Drug Delivery: A Special Emphasis on Polymeric Nanoparticles
Protein & Peptide Letters Endothelial Dysfunction and Coronary Artery Spasm
Current Drug Targets - Cardiovascular & Hematological Disorders Chemotherapy Delivery Strategies to the Central Nervous System: neither Optional nor Superfluous
Current Cancer Drug Targets Development and Validation of HPLC–PDA Method for the Quantitative Determination of Diphenyl Diselenide in Poly(lactide) Nanoparticles
Current Pharmaceutical Analysis Childhood Alopecia Areata: An Overview of Treatment and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Neuroprotective Gene Therapy for the Treatment of Inherited Retinal Degeneration
Current Gene Therapy Caspase Function in Neuronal Death: Delineation of the Role of Caspases in Ischemia
Current Drug Targets - CNS & Neurological Disorders Lipid Resuscitation: A Life-Saving Antidote for Local Anesthetic Toxicity
Current Pharmaceutical Biotechnology Antioxidants as Potentially Safe Antidotes for Organophosphorus Poisoning
Current Enzyme Inhibition Lactoferrin Suppresses Decreased Locomotor Activities by Improving Dopamine and Serotonin Release in the Amygdala of Ovariectomized Rats
Current Molecular Pharmacology Side Effects of Atypical Antipsychotic Drugs
Current Pharmaceutical Design Mental Health Patients at High Risk for Obesity, Type 2 Diabetes, and Cardiovascular Disease: An Australian Perspective
Current Hypertension Reviews Treatment of Cognitive Impairment in Schizophrenia: Potential Value of Phosphodiesterase Inhibitors in Prefrontal Dysfunction
Current Pharmaceutical Design Editorial [Hot topic: Adenosine Receptor Ligands: Where Are We, and Where Are We Going? (Guest Editors: Tiziano Tuccinardi and Adriano Martinelli)]
Current Topics in Medicinal Chemistry Adverse Drug Reactions in the Oral Cavity
Current Pharmaceutical Design